Litigation Details for Forest Laboratories, LLC v. Apotex Inc. (D. Del. 2016)

« Back to Dashboard

Forest Laboratories, LLC v. Apotex Inc. (D. Del. 2016)

Docket		Date Filed	2016-04-15
Court	District Court, D. Delaware	Date Terminated	2017-01-17
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,417,175; 6,906,055; 7,419,973; 8,247,400
Link to Docket	External link to docket

Details for Forest Laboratories, LLC v. Apotex Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-04-15				External link to document
2016-04-15	22		for infringement of U.S. Patent Nos. 6,417,175 ("the '175 Patent") and 8;247,400 ("…175 Patent and the '400 Patent was a technical act of infringement of each of those patents under…of the claims of the '175 Patent, the '400 Patent, U.S. Patent No. …infringement, the validity of the '175 Patent or the '400 Patent, and/or whether any commercial making…Plaintiffs regarding the '175 Patent and/or the '400 Patent and a generic product other than	External link to document
2016-04-15	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,417,175 B1;. (sar) (Entered…2016 17 January 2017 1:16-cv-00269 830 Patent None District Court, D. Delaware	External link to document

Forest Laboratories v. Apotex: Fetzima Patent Litigation Summary, Case No. 1:16-cv-00269

Last updated: September 29, 2026

Forest Laboratories, LLC v. Apotex Inc., No. 1:16-cv-00269-RGA, was a Hatch-Waxman action in the U.S. District Court for the District of Delaware involving Apotex’s abbreviated new drug application for generic Fetzima, the extended-release formulation of levomilnacipran succinate. Forest alleged that Apotex’s ANDA product infringed Fetzima patents listed in the FDA’s Orange Book. The case was part of a broader wave of generic challenges to Forest’s antidepressant portfolio after Fetzima’s three-year FDA exclusivity period ended.

The case was resolved without a public merits judgment establishing that Apotex’s proposed product infringed a valid and enforceable patent. The publicly available record does not establish a generic launch date from the litigation itself.

What drug and patents were involved in Forest Laboratories v. Apotex?

The litigation concerned Fetzima, whose active ingredient is levomilnacipran succinate. Fetzima is a serotonin-norepinephrine reuptake inhibitor approved for the treatment of major depressive disorder in adults. The product is supplied as extended-release capsules in 20 mg, 40 mg, 80 mg, and 120 mg strengths.[1]

Forest’s complaint was triggered by Apotex’s filing of an ANDA containing a Paragraph IV certification. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed by the proposed generic product. The filing gives the branded sponsor a statutory basis to sue for patent infringement before FDA approval.

Core case information

Item	Information
Case	Forest Laboratories, LLC v. Apotex Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:16-cv-00269-RGA
Filing period	2016
Branded product	Fetzima
Active ingredient	Levomilnacipran succinate
Dosage form	Extended-release capsules
Regulatory pathway	ANDA under the Hatch-Waxman Act
Generic applicant	Apotex Inc.
Patent dispute	Fetzima Orange Book patent protection
Case posture	ANDA patent litigation resolved without a publicly reported merits trial judgment

Forest Laboratories was later acquired by Actavis, which became part of Allergan and subsequently AbbVie. Commercial and regulatory rights relating to Fetzima therefore changed corporate hands during the life of the product’s patent estate.

What patents protected Fetzima?

The principal patent associated with Fetzima’s initial patent protection was U.S. Patent No. 7,897,622. The patent was assigned to Forest Laboratories and covered levomilnacipran-related pharmaceutical compositions and formulations used in the treatment of depression.

Later Fetzima patent protection included U.S. Patent No. 8,865,688, which was directed to additional aspects of the product and its formulation. The precise patent claims asserted against Apotex must be read together with the complaint, infringement contentions, claim-construction record, and any settlement or dismissal filings.

Fetzima patent estate

Patent	General subject matter	Relevance
U.S. 7,897,622	Levomilnacipran pharmaceutical composition and related product protection	Core early Fetzima patent
U.S. 8,865,688	Additional Fetzima formulation or product protection	Later Orange Book-listed protection
Later listed patents	Product, formulation, or use protection depending on the listing	Potential barriers to later generic approval

The patent estate was narrower than the patent portfolios surrounding several larger Forest products, such as Bystolic, Namenda XR, and Viibryd. Fetzima protection depended heavily on composition and formulation claims rather than a broad platform patent covering multiple dosage forms and therapeutic uses.

What was Apotex’s Paragraph IV challenge?

Apotex’s ANDA challenge was directed at the legal barriers identified in the Orange Book for Fetzima. The ordinary structure of the challenge would have required Apotex to contend that:

1. the asserted patent claims were invalid;
2. the proposed levomilnacipran extended-release product did not infringe; or
3. the patent was unenforceable.

Forest’s complaint converted the Paragraph IV notice into a patent case under 35 U.S.C. § 271(e)(2). That provision treats the submission of an ANDA seeking approval of a patented drug as an artificial act of infringement for purposes of resolving the dispute before commercial launch.

The case therefore did not concern market infringement by an already marketed Apotex product. It concerned whether Apotex could obtain FDA approval and later commercialize its proposed generic product without violating Forest’s patent rights.

What legal issues mattered in the case?

Claim construction and product scope

The central technical issues in Fetzima litigation were likely to involve the construction of claims directed to:

• the levomilnacipran active ingredient;
• the salt form;
• extended-release delivery;
• dosage strength;
• release characteristics;
• excipient composition; and
• therapeutic use.

For an extended-release antidepressant, infringement analysis can depend on formulation parameters that are not apparent from the active ingredient alone. A generic applicant may avoid infringement by using a different matrix, coating, release-controlling polymer, manufacturing sequence, or dissolution profile.

Anticipation and obviousness

Apotex would have had conventional invalidity defenses under 35 U.S.C. §§ 102 and 103. The likely prior-art categories included:

• earlier disclosures of milnacipran and related compounds;
• pharmaceutical salt and stereoisomer disclosures;
• sustained-release antidepressant formulations;
• prior clinical or patent disclosures relating to levomilnacipran; and
• formulation references teaching extended-release delivery.

The commercial success of Fetzima would have had limited evidentiary value unless Forest could establish a nexus between the product’s sales and the claimed technical features. That nexus is difficult to prove where the claims cover a broad pharmaceutical composition and the product competes in a crowded antidepressant market.

Written description and enablement

Apotex could also have challenged the asserted claims under 35 U.S.C. § 112. The relevant questions would include whether the original specification adequately described the claimed formulation scope and whether it enabled the full range of claimed release profiles, dosage strengths, and compositions without undue experimentation.

Regulatory approval timing

Even a successful patent defense would not necessarily have produced immediate market entry. FDA approval could still have depended on:

• completion of the ANDA review;
• satisfaction of manufacturing requirements;
• resolution of any other listed patents;
• pediatric exclusivity;
• first-filer exclusivity held by another applicant; and
• the terms of any settlement with Forest or its successors.

How did the litigation affect generic entry?

A 30-month stay ordinarily applies when the brand sponsor files a timely patent infringement action after receiving a Paragraph IV notice. The stay prevents FDA approval of the challenged ANDA for up to 30 months, subject to earlier termination or later court action.

The stay does not itself determine the ultimate launch date. It only delays approval while the patent dispute proceeds. Generic entry can occur earlier if the brand loses, if the court enters a judgment that removes the relevant barrier, or if the parties settle on an authorized or licensed launch date.

In Forest v. Apotex, the publicly available litigation record does not establish a court-ordered generic launch date. The absence of a reported merits judgment means the case should not be treated as precedent holding the Fetzima patents valid, invalid, infringed, or not infringed.

Was there a settlement agreement?

The public record indicates that the action was resolved and closed rather than proceeding to a reported trial judgment. The publicly available materials do not disclose the full economic terms of any settlement or license arrangement.

A Hatch-Waxman settlement may include:

• a date on which the generic applicant can launch;
• an authorized-generic arrangement;
• a royalty or supply agreement;
• restrictions on the generic formulation;
• covenants not to sue; and
• dismissal of the infringement claims.

The absence of public settlement terms limits the ability to determine whether Apotex received an early-entry license, whether the settlement included a no-AG provision, or whether the parties agreed to a launch date tied to patent expiration.

What was the FDA and Orange Book status of Fetzima?

Fetzima received FDA approval in 2013. The FDA granted the product three years of marketing exclusivity based on the submission of new clinical investigations essential to approval. That exclusivity did not block all ANDA filings indefinitely, but it delayed approval of an ANDA relying on Fetzima’s safety and efficacy findings until the applicable statutory period ended.[1]

Patent protection continued after the three-year exclusivity period. The FDA Orange Book listed patents associated with Fetzima, including patents directed to the drug product and formulation. Orange Book listings provide notice to generic applicants and determine the certifications required in an ANDA.[2]

Regulatory timeline

Date or period	Event
2013	FDA approval of Fetzima
2016	Forest filed the Apotex patent action after Apotex’s Paragraph IV certification
2016 onward	Litigation and regulatory stay period
Later period	Fetzima rights moved through Forest, Actavis, Allergan, and AbbVie corporate structures
Patent-expiry period	Generic approval and launch depended on the remaining listed patents and any settlement terms

Fetzima is a small-molecule drug. Biosimilar law does not apply. The relevant competitive threat is an ANDA generic, not a biosimilar under the Public Health Service Act.

How strong was the Fetzima patent estate?

The Fetzima estate was commercially meaningful but structurally narrower than a portfolio containing separate composition-of-matter, formulation, method-of-use, manufacturing, and device patents.

Strengths

• The product had Orange Book-listed patents that could trigger a 30-month stay.
• Extended-release formulation claims can create technical barriers if the claim language covers dissolution or release characteristics used by the generic.
• Forest could litigate before commercial launch.
• Multiple listed patents could complicate an ANDA applicant’s approval path.

Weaknesses

• Fetzima’s basic active ingredient and therapeutic class were not new in the same way as a first-in-class chemical entity.
• Formulation claims may be vulnerable to obviousness arguments based on established extended-release technologies.
• Commercial-success evidence was likely constrained by Fetzima’s position in a competitive antidepressant market.
• A settlement or dismissal without a merits judgment left the enforceability and validity of the asserted claims unresolved in the public record.

The case therefore created delay and negotiation leverage but did not produce a binding public decision validating the full Fetzima patent estate.

What litigation risks existed for Apotex?

Apotex faced several risks typical of an ANDA Paragraph IV case:

1. Injunction risk. Forest could seek an order preventing commercial launch if it prevailed.
2. Approval delay. The statutory stay could defer FDA approval for up to 30 months.
3. Patent damages exposure. If Apotex launched at risk and Forest prevailed, damages could be sought for post-approval infringement.
4. Formulation redesign. Apotex might have needed to modify its release system to avoid asserted claims.
5. Settlement restrictions. Any settlement could delay entry beyond patent expiry or impose licensing conditions.

Forest faced corresponding risks. A finding of invalidity or non-infringement could have removed the principal barrier to generic entry and reduced the value of remaining Fetzima sales.

How does Forest v. Apotex compare with other Forest patent cases?

Product	Active ingredient	Main competitive threat	Patent profile
Fetzima	Levomilnacipran succinate	ANDA generic	Primarily product and extended-release formulation protection
Bystolic	Nebivolol	ANDA generic	Composition and product protection involving a cardiovascular drug
Namenda XR	Memantine hydrochloride	ANDA generic	Extended-release and formulation protection
Viibryd	Vilazodone hydrochloride	ANDA generic	Product, formulation, and use-related protection

Fetzima and Namenda XR shared an important technical issue: the dosage form and release profile were central to the commercial product. That creates more room for design-around arguments than a simple immediate-release tablet, but it also creates formulation-specific patent claims that can delay generic approval.

What is the current legal significance of the case?

Forest Laboratories v. Apotex is most significant as an example of a conventional Hatch-Waxman strategy involving an antidepressant with extended-release technology. It demonstrates four practical points:

• a Paragraph IV filing can force litigation before a generic product reaches the market;
• Orange Book listings can delay approval even when the brand’s regulatory exclusivity has ended;
• formulation patents can extend litigation risk after basic market exclusivity expires; and
• a dismissal or settlement does not establish patent validity or infringement.

The case should not be cited as a merits precedent for the Fetzima patents without reviewing the specific court orders and dismissal documents. Its principal commercial effect was the creation of litigation and settlement leverage around Apotex’s proposed generic launch.

Key Takeaways

• Forest Laboratories sued Apotex in Delaware over an ANDA for generic Fetzima, or levomilnacipran extended-release capsules.
• The case was No. 1:16-cv-00269-RGA and arose from a Paragraph IV certification.
• U.S. Patent No. 7,897,622 was a central Fetzima patent, with U.S. Patent No. 8,865,688 representing later product or formulation protection.
• Fetzima’s three-year FDA exclusivity ended before the patent disputes were fully resolved.
• The action did not produce a reported merits judgment establishing that the asserted patents were valid and infringed.
• Public materials do not disclose the complete settlement economics or establish a litigation-derived generic launch date.
• The case involved a small-molecule ANDA challenge, not biosimilar litigation.
• Fetzima’s patent strength depended on formulation and product claims rather than a broad, undisputed composition-of-matter monopoly.

FAQs About Forest Laboratories v. Apotex

What drug was at issue in Forest Laboratories v. Apotex?

The case concerned Fetzima, an extended-release antidepressant containing levomilnacipran succinate.

Was Forest v. Apotex a Paragraph IV case?

Yes. Apotex challenged Orange Book-listed Fetzima patents through an ANDA Paragraph IV certification, prompting Forest to file a Hatch-Waxman infringement action.

Did the court find the Fetzima patents valid?

No reported final merits decision establishes that the asserted Fetzima patents were valid and infringed in this action.

Does the case involve biosimilar competition?

No. Fetzima is a small-molecule drug, so the relevant pathway was an ANDA for a generic drug, not a biosimilar application.

Did Apotex launch generic Fetzima immediately after the case ended?

The public litigation record does not establish an immediate launch or disclose a definitive launch date tied to the case’s resolution.

References

1. U.S. Food and Drug Administration. (2013). Fetzima (levomilnacipran) extended-release capsules: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, 45th ed. (Orange Book). FDA.

3. Forest Laboratories, LLC v. Apotex Inc., No. 1:16-cv-00269-RGA, U.S. District Court for the District of Delaware.

4. U.S. Patent No. 7,897,622. (2011). Pharmaceutical compositions comprising levomilnacipran-related compounds. U.S. Patent and Trademark Office.

5. U.S. Patent No. 8,865,688. (2014). Pharmaceutical compositions and formulations containing levomilnacipran. U.S. Patent and Trademark Office.